Pharmaceuticals

FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma

bexib
By bexib 0 Min Read

Breyanzi, a CD19-targeted CAR T cell therapy, has received its fourth FDA approval to treat a specific subtype of non-Hodgkin lymphoma.

You Might Also Like

Pharma Pulse 7/15/24: Merck completes iBio acquisition, companies sharply criticize draft US cyber reporting rules, etc.

FDA Approves Verona’s Otovile for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Lilly’s donanemab faces Alzheimer’s treatment in June, setting stage for showdown with Rekenbi

2024 Pharm Exec Top 50 Companies

Personify Health provides employers with best practices for GLP-1 coverage options

Share This Article
Previous Article What Is Product Development? 7 Steps to Making a Product (2024)
Next Article Press buttons, turn knobs, Bleepler synth toy
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Krebs & Riedel Abrasives India envisions the future of grinding technology
Manufacturing
dtcpay and BNB Chain power the ecosystem for real-world stablecoin usage
Fintech
The Path Forward – Machine Insider
Manufacturing
How India’s UPI makeover and WhatsApp Pay expansion will transform banking
Fintech